<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01546116</url>
  </required_header>
  <id_info>
    <org_study_id>ALTER_114093</org_study_id>
    <nct_id>NCT01546116</nct_id>
  </id_info>
  <brief_title>Adefovir and Lamivudine for Entecavir Resistance (ALTER Study)</brief_title>
  <acronym>ALTER</acronym>
  <official_title>Efficacy of Adefovir and Lamivudine Combination Therapy in Patients With Entecavir Resistance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Korea University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Entecavir has been one of the option for treatment of lamivudine resistant chronic
           hepatitis B (CHB).

        -  In case of entecavir resistance, adefovir could be used. However, sequential monotherapy
           may result in multidrug resistance.

        -  It is thought that adefovir and lamivudine combination therapy reduce the risk of
           adefovir resistance, thereby continued therapy will lead to suppression of hepatitis B
           virus (HBV) DNA to be undetectable in patients with entecavir resistance.

        -  This study aim to evaluate the efficacy of adefovir and lamivudine combination therapy
           in CHB patients with entecavir resistance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Entecavir is a potent antiviral agent for the treatment of chronic hepatitis B (CHB).
      However, the incidence of entecavir resistance increases over 50% at 5th year in
      lamivudine-refractory CHB patients. Considering cross resistance profile, adefovir is a good
      option for managing entecavir resistance. However adefovir monotherapy may lead to adefovir
      resistance, because entecavir resistant hepatitis B virus (HBV) retain lamivudine resistance.
      Previously, combination of adefovir and lamivudine was reported to be effective in a patient
      with entecavir resistance, but only as a case report form. No further data are available on
      this combination therapy in a sufficient number of patients. It is thought that adefovir and
      lamivudine combination therapy reduce the risk of adefovir resistance, thereby continued
      combination treatment will result in suppression of HBV DNA to be undetectable in patients
      with entecavir resistance.

      The aim of this study is to evaluate the efficacy of adefovir and lamivudine combination
      therapy in CHB patients with entecavir resistance.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Degree of HBV DNA reduction from baseline</measure>
    <time_frame>at week 52</time_frame>
    <description>Degree of HBV DNA reduction from baseline during 52 week-period of adefovir and lamivudine combination therapy will be assessed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HBV DNA undetectability by PCR (&lt;60 IU/mL)</measure>
    <time_frame>at week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALT normalization</measure>
    <time_frame>at week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBeAg loss</measure>
    <time_frame>at week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBeAg to anti- HBe seroconversion</measure>
    <time_frame>at week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of adefovir resistance</measure>
    <time_frame>at week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic breakthrough</measure>
    <time_frame>at week 52</time_frame>
    <description>virologic breakthrough is defined by increase of HBV DNA above 10 times the lowest level (na dir).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Adefovir and lamivudine combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADEFOVIR, LAMIVUDINE</intervention_name>
    <description>Adefovir/10mg tablet/once a day/52week Lamivudine/100mg tablet/once a day/52week</description>
    <arm_group_label>Adefovir and lamivudine combination</arm_group_label>
    <other_name>Adefovir (Hepasera)</other_name>
    <other_name>Lamivudine (Zeffix)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Chronic hepatitis B patients (positive HBsAg &gt; 6 months)

          2. Age &gt; 18 year old

          3. History of treatment with entecavir more than 6 months

          4. Proven entecavir resistant mutation (rtT184S/A/I/L/G/C/M, rtS202G/C/I, or rtM250I/V)

          5. HBV DNA level&gt; 2000 IU/mL

          6. Compensated liver disease (Child-Pugh-Turcotte score over 7; prothrombin time
             prolonged more than 3 sec above ULN or INR over 1.5; serum albumin &gt;3 g/dL; total
             bilirubin &lt;2.5 mg/dL; No history of variceal bleeding, ascites, or hepatic
             encephalopathy)

          7. Patients willing to give informed consent

        Exclusion Criteria:

          1. Out of inclusion criteria

          2. Any one of following

               -  Serum phosphorus level under 2.4 mg/dL

               -  Serum creatinine level over 1.5 mg/dL or creatinine clearance &lt;50 mL/min

               -  Absolute neutrophil count lower than 1000 cell/mL

               -  Hb level under 10 g/dL (male), under 9 g/dL (female)

               -  Serum AFP &gt;100 ng/mL

          3. History of treatment with interferon-alfa, thymosin-alfa 1, or nucleos(t)ide analogue
             other than entecavir in 6 months of screening

          4. History of adefovir resistance (detection of rtA181T/Vor rtN236T at screening or in
             the past)

          5. Recipient of organ transplantation

          6. Positive antibody test to HIV, HCV or HDV

          7. Pregnant or breast feeding women

          8. Patients with hepatocellular carcinoma or uncontrolled malignant disease

          9. Habitual alcohol drinker (&gt;140 g/week for men, &gt;70 g/week for women) -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>HYUNG JOON YIM, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chungbuk National University Hospital</name>
      <address>
        <city>Cheongju</city>
        <state>Chngcheongbuk-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yonsei University Wonju Christian Hospital</name>
      <address>
        <city>Wonju</city>
        <state>Gangwon-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hallym University, Sacred Heart Hospital</name>
      <address>
        <city>Anyang</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Euijeongbu Saint Mary's Hospital</name>
      <address>
        <city>Euijeongbu</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Ansan Hospital</name>
      <address>
        <city>Ansan</city>
        <state>Gyeonggi</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Medical Center</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hallym University, Gangnam Sacred Heart Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Lee WM. Hepatitis B virus infection. N Engl J Med. 1997 Dec 11;337(24):1733-45. Review.</citation>
    <PMID>9392700</PMID>
  </reference>
  <reference>
    <citation>Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009 Sep;50(3):661-2. doi: 10.1002/hep.23190.</citation>
    <PMID>19714720</PMID>
  </reference>
  <reference>
    <citation>Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, Wichroski MJ, Xu D, Yang J, Wilber RB, Colonno RJ. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology. 2009 May;49(5):1503-14. doi: 10.1002/hep.22841.</citation>
    <PMID>19280622</PMID>
  </reference>
  <reference>
    <citation>Yim HJ, Hussain M, Liu Y, Wong SN, Fung SK, Lok AS. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology. 2006 Sep;44(3):703-12.</citation>
    <PMID>16941700</PMID>
  </reference>
  <reference>
    <citation>Lampertico P, Viganò M, Manenti E, Iavarone M, Sablon E, Colombo M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology. 2007 Nov;133(5):1445-51. Epub 2007 Sep 2.</citation>
    <PMID>17983801</PMID>
  </reference>
  <reference>
    <citation>Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology. 2007 Feb;45(2):307-13.</citation>
    <PMID>17256746</PMID>
  </reference>
  <results_reference>
    <citation>Villet S, Ollivet A, Pichoud C, Barraud L, Villeneuve JP, Trépo C, Zoulim F. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J Hepatol. 2007 Mar;46(3):531-8. Epub 2006 Dec 18.</citation>
    <PMID>17239478</PMID>
  </results_reference>
  <results_reference>
    <citation>Yatsuji H, Hiraga N, Mori N, Hatakeyama T, Tsuge M, Imamura M, Takahashi S, Fujimoto Y, Ochi H, Abe H, Maekawa T, Suzuki F, Kumada H, Chayama K. Successful treatment of an entecavir-resistant hepatitis B virus variant. J Med Virol. 2007 Dec;79(12):1811-7.</citation>
    <PMID>17935165</PMID>
  </results_reference>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2011</study_first_submitted>
  <study_first_submitted_qc>March 1, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2012</study_first_posted>
  <last_update_submitted>February 14, 2014</last_update_submitted>
  <last_update_submitted_qc>February 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Korea University</investigator_affiliation>
    <investigator_full_name>Hyung Joon Yim</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>adefovir</keyword>
  <keyword>lamivudine</keyword>
  <keyword>entecavir resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Adefovir</mesh_term>
    <mesh_term>Adefovir dipivoxil</mesh_term>
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

